Britain and America have concluded a landmark bilateral deal that will maintain zero duties on British pharmaceutical exports being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these vital products will stay at zero for a period of three years.
This agreement follows earlier threats to hike tariffs on patented pharmaceutical products, with increases discussed up to one hundred percent.
"This deal with the United Kingdom bolsters the global environment for new treatments and brings long-overdue fairness to transatlantic pharmaceutical trade," a statement noted.
Economic Impact
Medicines represent one of the the United Kingdom's most significant export categories to the US, which is clearly the primary buyer for leading UK drugmakers.
Statistics show that in the 12 months to the end of the third quarter, the UK sold pharmaceutical products totaling billions to the US. This value represented a significant portion of British export trade in that period.
"This agreement safeguards work, stimulates funding and facilitates the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Key UK Commitments
The agreement entails several specific changes from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to raise total health service expenditure on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. Last year, refunds topped 20%.
Industry Background
The deal takes place against a long-running row between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
This friction were heightened by claims that American consumers were paying several times more for the identical medicines than people in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward American operations.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its expenditure on drugs had decreased as a share of its resources over the past decade.
